Measuring the bile acid receptor FXR: bridging preclinical detection and screening technologies to clinical biomarkers and translational applications

The farnesoid X receptor (FXR; NR1H4 ) is a ligand-activated nuclear receptor that coordinates bile acid, lipid, and glucose homeostasis and has emerged as a validated therapeutic target in cholestatic liver disease and a target in late-stage clinical development in metabolic dysfunction-associated steatohepatitis, though no agent in this class has yet demonstrated a confirmed clinical benefit in that disease. However, the field remains anchored in preclinical and mechanistic research: translation of FXR biology into clinical applications remains limited, and although better measurement is a necessary but not sufficient contribution to that translation—alongside efficacy, safety, and tissue-dependent pharmacology—what we can measure are FXR’s ligand binding, its transcriptional activity, and the downstream outputs it controls. Here we review technologies for the detection and screening of FXR and its ligands, organized along the receptor’s ligand-dependent activation cascade, and trace how these preclinical tools connect to clinical biomarkers that are beginning to guide FXR-targeted therapy. We first describe the molecular basis of FXR detection, then survey cell-free ligand-binding assays, receptor conformational and coactivator-recruitment assays, transcriptional readouts, and structural methods, followed by high-throughput and virtual screening approaches. We then examine the translational gap that separates in vitro measurement from patient-level readouts, and review the clinical biomarkers of FXR activity—led by circulating fibroblast growth factor 19 (FGF19) and the bile acid synthesis intermediate 7α-hydroxy-4-cholesten-3-one (C4)—together with their emerging roles in pharmacodynamic monitoring, patient stratification, and companion diagnostics and imaging. We conclude by scoping the remaining challenges and identifying the measurement questions that would have to be answered before FXR pathway assessment could support individualized therapy—a step that remains aspirational rather than demonstrated.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.2011401
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Measuring the bile acid receptor FXR: bridging preclinical detection and screening technologies to clinical biomarkers and translational applications

Peiling Zhong, Liubin Xu, Yuxiang Liu, Kai Sang et al.
Frontiers in Pharmacology
Drug Transport and Resistance Mechanisms
article

Measuring the bile acid receptor FXR: bridging preclinical detection and screening technologies to clinical biomarkers and translational applications

Peiling Zhong, Liubin Xu, Yuxiang Liu, Kai Sang, Bingbing Zhang, Jianping Lai, Mingshun Li, Jiyong Lin, Sheng Chen, Lei Liu, Liang Chen
article en

Abstract

The farnesoid X receptor (FXR; NR1H4 ) is a ligand-activated nuclear receptor that coordinates bile acid, lipid, and glucose homeostasis and has emerged as a validated therapeutic target in cholestatic liver disease and a target in late-stage clinical development in metabolic dysfunction-associated steatohepatitis, though no agent in this class has yet demonstrated a confirmed clinical benefit in that disease. However, the field remains anchored in preclinical and mechanistic research: translation of FXR biology into clinical applications remains limited, and although better measurement is a necessary but not sufficient contribution to that translation—alongside efficacy, safety, and tissue-dependent pharmacology—what we can measure are FXR’s ligand binding, its transcriptional activity, and the downstream outputs it controls. Here we review technologies for the detection and screening of FXR and its ligands, organized along the receptor’s ligand-dependent activation cascade, and trace how these preclinical tools connect to clinical biomarkers that are beginning to guide FXR-targeted therapy. We first describe the molecular basis of FXR detection, then survey cell-free ligand-binding assays, receptor conformational and coactivator-recruitment assays, transcriptional readouts, and structural methods, followed by high-throughput and virtual screening approaches. We then examine the translational gap that separates in vitro measurement from patient-level readouts, and review the clinical biomarkers of FXR activity—led by circulating fibroblast growth factor 19 (FGF19) and the bile acid synthesis intermediate 7α-hydroxy-4-cholesten-3-one (C4)—together with their emerging roles in pharmacodynamic monitoring, patient stratification, and companion diagnostics and imaging. We conclude by scoping the remaining challenges and identifying the measurement questions that would have to be answered before FXR pathway assessment could support individualized therapy—a step that remains aspirational rather than demonstrated.

Frontiers in PharmacologyVol. 17
Guangzhou University of Chinese Medicine (CN), Shenzhen Traditional Chinese Medicine Hospital (CN)
Good health and well-being
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon